Drug intelligence / Profile preview

NNC0165-1875

Development stage: Phase 2
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC0165-1875 is a synthetic peptide analogue of the appetite-regulating hormone peptide YY (PYY), specifically designed as a long-acting agonist of the neuropeptide Y receptor type 2 (NPY2R). Developed by Novo Nordisk, it is intended for once-weekly subcutaneous administration to treat obesity. The drug mimics the action of endogenous PYY3–36, which reduces appetite and food intake by activating Y2 receptors in the brain, particularly within hypothalamic pathways involved in satiety regulation. As of late 2022, NNC0165-1875 has completed phase II clinical trials for obesity, including studies evaluating its use both as monotherapy and in combination with semaglutide[1][2][4][6][7].

Other names: PYY-1875PYY1875PYY 1875

Targets

NPY2R (Neuropeptide Y receptor subtype 2)

Beyond the preview

Go deeper on NNC0165-1875.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0165-1875.

Explore the full profile